

1 **Activation of the epidermal growth factor receptor initiates innate immune responses**
2 **during oropharyngeal candidiasis**

3

4 Running title: EGFR triggers innate immune responses

5 Marc Swidergall^{1, 2 *}, Norma V. Solis^{1, 2}, Quynh T. Phan^{1, 2}, Michael D. Lazarus¹, Zeping Wang^{1, #},

6 Scott G. Filler^{1, 2, 3, *}

7

8 **Affiliations**

9 ¹ Division of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, California 90502, USA

10 ² Institute for Infection and Immunity, Los Angeles Biomedical Research Institute at Harbor-UCLA

11 Medical Center, Torrance, California 90502, USA

12 ³ David Geffen School of Medicine at UCLA, Los Angeles, California 90024, USA

13

14 [#]Current address: Center for Infectious Disease Imaging (CIDI), Radiology and Imaging Sciences,

15 NIH Clinical Center, National Institutes of Health (NIH), Bethesda, Maryland 20892, USA

16

17 *Correspondence to: mswidergall@labiomed.org; sfiller@ucla.edu

18

19 **Abstract**

20 The induction of antifungal proinflammatory signaling during oropharyngeal candidiasis (OPC) is
21 crucial to limit *Candida albicans* proliferation and induce fungal clearance. Previously, we
22 determined that the ephrin type-A receptor 2 (EphA2) functions as a β -glucan receptor that senses
23 oral epithelial cell fungal burden. EphA2 plays a central role in stimulating the epithelial cell
24 release of proinflammatory mediators that mediate resistance to OPC. Another receptor for *C.*
25 *albicans* is the epidermal growth factor receptor (EGFR), which interacts with candidal invasins
26 such as Als3 interact and induces epithelial cells to endocytose the fungus. Here, we investigated
27 the interactions between EGFR and EphA2. We found that EGFR and EphA2 constitutively
28 associated with each other as part of a physical complex. Activation of EGFR by *C. albicans* Als3
29 was required for sustained EphA2 phosphorylation and for induction of CXCL8/IL-8 and CCL20
30 secretion by epithelial cells. Treatment of uninfected epithelial cells with IL-17A and TNF α also
31 induced EGFR phosphorylation, which was necessary for epithelial cells to respond to these
32 cytokines. In mice with OPC, pharmacological inhibition of EGFR during caused a modest
33 reduction in oral fungal burden, markedly impaired production of proinflammatory cytokines and
34 significantly decreased accumulation of neutrophils and inflammatory monocytes. Thus, while *C.*
35 *albicans* activation of EGFR mediates fungal invasion of the epithelium, it also sustains EphA2
36 signaling, inducing the epithelial cell proinflammatory response to the fungus.

37

38

39 **Importance**

40 Host cell receptors for fungi have typically been evaluated from one of two different perspectives,
41 their role in inducing the invasion of the organism or their role in stimulating the host inflammatory
42 response. We had found previously that EGFR mediates the endocytosis of *C. albicans* by oral
43 epithelial cells, and that epithelial cell EphA2 mediates the production of chemokines and
44 proinflammatory cytokines in response to *C. albicans*. Here, we demonstrate that EGFR and
45 EphA2 interact with each other, both physically and functionally. EGFR is required for sustained
46 EphA2 activation and for epithelial cells to secrete proinflammatory mediators in response to both
47 *C. albicans* and IL-17A. Therefore, while activation of EGFR by *C. albicans* enhances
48 pathogenicity by inducing the endocytosis of the fungus, it also augments the host defense
49 against OPC by stimulating the host inflammatory response.

50

51 **Keywords:** *Candida albicans*, oropharyngeal candidiasis, epithelial cell, receptor, inflammatory
52 response, endocytosis, invasin, IL-17

53 **Introduction**

54 The human oral cavity hosts a multifaceted microbiome comprised of an estimated 600
55 bacterial and 100 fungal species (1). Among these fungal species is *Candida albicans*, which
56 grows as a harmless commensal in at least 50% of healthy adults. When there is an imbalance
57 of local or systemic immune homeostasis, *C. albicans* can proliferate, causing oropharyngeal
58 candidiasis (OPC) (2). While this disease is relatively uncommon in healthy adults, it causes
59 significant morbidity in a large, diverse population of patients, including those with HIV/AIDS,
60 xerostomia, corticosteroid use, diabetes mellitus, and cancer of the head and neck. Each year,
61 there are nearly 10 million cases of OPC in patients with HIV/AIDS world-wide, and nearly one
62 fifth of these cases have esophageal involvement (3).

63 At least 80% of cases of OPC are caused by *C. albicans*. When this organism overgrows
64 in the oropharynx, there is invasion of the superficial epithelium, leading to host cell death (4).
65 One mechanism by which *C. albicans* invades oral epithelial cells is receptor mediated
66 endocytosis. In this process, invasins, such as Als3 and Ssa1 expressed on the surface of *C.*
67 *albicans* hyphae interact with epithelial cell receptors such as E-cadherin and a heterodimer
68 composed of the epidermal growth factor (EGFR) and HER2. This interaction triggers
69 rearrangement of the epithelial cell cytoskeleton, leading to the formation of pseudopods that
70 engulf the organism and pull it into the host cell (4-7).

71 The epithelial cells that line the oropharynx sense the presence of *C. albicans* and
72 orchestrate the host inflammatory response to fungal overgrowth. In addition to producing host
73 defense peptides that have direct antifungal activity, oral epithelial cells secrete alarmins,
74 proinflammatory cytokines, and chemokines that recruit phagocytes to foci of infection and
75 enhance their candidacidal activity to limit the growth of the invading fungi (8-10). This epithelial
76 cell response to OPC is amplified by interleukin (IL)-17, which is secreted by $\gamma\delta$ T cells, innate
77 TCR $\alpha\beta^+$ cells, and type-3 innate lymphoid cells (11-14). Recently we determined that the ephrin
78 type-A receptor 2 (EphA2) is expressed on oral epithelial cells and senses exposed β -glucan on

79 the fungal surface. When *C. albicans* proliferates on the epithelial cell surface, EphA2 is activated
80 and oral epithelial cells secrete host defense peptides and proinflammatory mediators. In mice
81 with OPC, EphA2 also induces the production of IL-17A, and *EphA2*^{-/-} mice are highly susceptible
82 to OPC (15).

83 Although EphA2 is required for the normal host defense against OPC, exposure of oral
84 epithelial cells to purified β -glucan induces only transient EphA2 activation and is not sufficient to
85 initiate a significant inflammatory response. By contrast, exposure to live *C. albicans* induces
86 sustained EphA2 activation and a strong inflammatory response (15). In the current study, we
87 sought to elucidate how *C. albicans* infection prolongs EphA2 activation and induces a
88 proinflammatory response during OPC. We found that activation of host EGFR by *C. albicans*
89 Als3 maintained EphA2 phosphorylation and was required for the fungus to stimulate oral
90 epithelial cells to produce the chemokines, CXCL8/IL-8 and CCL20. Treatment of uninfected
91 epithelial cells with IL-17A and TNF α induced transient phosphorylation of EGFR, which was
92 necessary for epithelial cells to respond to IL-17A. In mice with OPC, pharmacological inhibition
93 of EGFR caused a modest reduction in oral fungal burden and a markedly impaired inflammatory
94 response. Thus, while *C. albicans* activation of EGFR mediates fungal invasion of the epithelium,
95 it is also plays a central role in inducing the local inflammatory response to this fungus.

96

97 **Results**

98 **The cellular fate of epithelial EphA2 differs depending on the type of stimulation.**
99 When oral epithelial cells are infected with yeast-phase *C. albicans*, the organisms germinate and
100 begin to form hyphae within 60 min. Previously, we found that EphA2 is autophosphorylated on
101 serine 897 within 15 min of infection, and it remains phosphorylated for at least 90 min. By
102 contrast, when oral epithelial cells are exposed to β -glucan in the form of zymosan or laminarin,
103 EphA2 is phosphorylated for only the first 30 min of contact; at later time points, EphA2
104 phosphorylation returns to basal levels, even though β -glucan is still present (15). To investigate

105 how oral epithelial cells respond to prolonged EphA2 stimulation, we compared the response of
106 these cells to the native EphA2 ligand, ephrin A1 (EFNA1) and to *C. albicans*. After 15 min of
107 exposure, both stimuli induced phosphorylation of EphA2 (Fig. 1A; S1). However, after 60 min,
108 the cells exposed to EFNA1 had minimal phosphorylation of EphA2, and total EphA2 levels had
109 declined (Fig. 1B; S1). By contrast, the cells exposed to *C. albicans* had sustained EphA2
110 phosphorylation and no decrease in total EphA2 levels. Thus, exposure to *C. albicans* not only
111 induces EphA2 phosphorylation, but prevents subsequent EphA2 dephosphorylation and
112 degradation that normally occurs with prolonged exposure to its native ligand EFNA1 (16).

113 **EGFR sustains *C. albicans*-induced EphA2 activation and constitutively interacts**
114 **with EphA2.** Previously, we determined that EphA2 and EGFR function in the same pathway to
115 mediate the endocytosis of *C. albicans* by oral epithelial cells. Also, EphA2 is required for
116 *C. albicans* to activate EGFR because siRNA knockdown of EphA2 in oral epithelial cells blocks
117 phosphorylation of EGFR induced by the fungus (15). Cross talk between EphA2 and EGFR has
118 also been observed in other cell types (17, 18). To investigate the nature of this cross-talk, we
119 tested the effects of inhibiting EGFR on *C. albicans*-induced EphA2 activation. When EGFR was
120 either knocked down with siRNA or inhibited with the specific EGFR kinase inhibitor, gefitinib (19),
121 EphA2 phosphorylation was transient, occurring within 30 min of infection, but declining to basal
122 levels by 90 min (Fig. 1C, D; S1). Therefore, activation of EGFR by *C. albicans* is required to
123 sustain EphA2 phosphorylation.

124 One potential mechanism for the cross-talk between EphA2 and EGFR is a physical
125 interaction between these two receptors. We investigated this possibility by immunoprecipitation
126 experiments. When EphA2 was immunoprecipitated from lysates of epithelial cells, EGFR was
127 pulled down; the amount of EGFR that was associated with EphA2 did not increase when the
128 epithelial cells were infected with *C. albicans* (Fig. 1E, F). In reciprocal experiments, we
129 determined that immunoprecipitation of EGFR from infected and uninfected epithelial cells pulled
130 a constant amount of EphA2 (Fig. 1E, F). These results indicate that EphA2 and EGFR

131 constitutively associate with each other, likely forming part of a complex that enables each
132 receptor to influence the activity of the other.

133 **EGFR induces a subset of EphA2-mediated pro-inflammatory responses in oral**
134 **epithelial cells.** The physical association of EphA2 with EGFR suggested the possibility that
135 EGFR may also induce the epithelial cell proinflammatory response to *C. albicans* infection. To
136 test this hypothesis, we compared the effects of siRNA knockdown of EGFR and EphA2 on
137 cytokine production in oral epithelial cells that were infected with *C. albicans*. We found that
138 knockdown of EGFR inhibited the secretion of CXCL8/IL-8 and CCL20 similarly to knockdown of
139 EphA2 (Fig. 2A). Although knockdown of EGFR had no effect on the release of IL-1 α , and IL-1 β ,
140 knockdown of EphA2 blocked both of these cytokines. Treatment of the epithelial cells with
141 gefitinib had a similar effect to siRNA knockdown of EGFR, resulting in inhibition of CXCL8/IL-8
142 and CCL20 secretion but no reduction of IL-1 α , and IL-1 β release (Fig. 2B). These results suggest
143 that EGFR governs a subset of the epithelial cell inflammatory response to *C. albicans* infection.

144 ***C. albicans* Als3 is required for prolonged EphA2 activation and induction of**
145 **epithelial cell chemokine and cytokine secretion.** The *C. albicans* invasin Als3 activates EGFR
146 and induces oral epithelial cells to endocytose the fungus (Fig. S2) (5, 20). To determine if Als3
147 also activates EphA2, we analyzed the response of oral epithelial cells to infection with an *als3* Δ/Δ
148 null mutant. As expected, this mutant induced weak EGFR autophosphorylation and was
149 endocytosed poorly (Fig. 3A, B, S2). Infection with the *als3* Δ/Δ null mutant induced transient
150 EphA2 phosphorylation that returned to basal level by 90 min of infection (Fig.3C; S3). Infection
151 with the *als3* Δ/Δ null mutant also caused significantly less secretion of CXCL8/IL-8, CCL20, IL-1 α ,
152 and IL-1 β (Fig. 3D). Collectively, these results indicate that *C. albicans* Als3 activates EGFR,
153 which prolongs EphA2 phosphorylation and stimulates oral epithelial cells to secrete chemokines
154 and pro-inflammatory cytokines.

155 **Inhibition of EGFR impairs the host inflammatory response during OPC.** To further
156 assess the role of EGFR in mediating the host inflammatory response to *C. albicans* during OPC,

157 we treated immunocompetent mice with gefitinib (20, 21) and then orally inoculated them with
158 *C. albicans*. Using immunostaining with phosphospecific antibodies, we assessed the effects of
159 gefitinib on EGFR and EphA2 phosphorylation in the oral epithelium. Similar to its effects *in vitro*,
160 treatment with gefitinib reduced the phosphorylation of both EGFR and EphA2 after 1 d of infection
161 (Fig. 4A, B). At this time point, the gefitinib-treated mice had a 3-fold reduction in oral fungal
162 burden compared to untreated mice (Fig. 4C). The oral tissues of gefitinib-treated mice also
163 contained significantly less IL-1 α , IL-1 β , CXCL1/KC, IL-17A, and the p19 subunit of IL-23 than the
164 control mice (Fig. 5A). By contrast, the levels of CCL2, CCL3, CCL4, and the host defense peptide
165 S100A8 in the gefitinib treated mice were not significantly different from the control mice,
166 indicating that gefitinib selectively inhibited a subset of the host inflammatory response. Treatment
167 with gefitinib also caused a dramatic reduction in the number of neutrophils and inflammatory
168 monocytes in the oral tissues relative to the mice (Fig. 5B, C, S4). Thus, in immunocompetent
169 mice, gefitinib inhibits *C. albicans*-induced phosphorylation of EGFR and EphA2, thereby reducing
170 both oral fungal burden and the host inflammatory response.

171 Because gefitinib impaired the host inflammatory response to *C. albicans*, we investigated
172 its effects on the candidacidal activity of neutrophils and macrophages. We found that gefitinib
173 did not decrease the capacity of human neutrophils or mouse bone marrow derived macrophages
174 to kill *C. albicans* *in vitro* (Fig. S5). Taken together, these results indicate that while EGFR
175 signaling is required for epithelial cells to mount a pro-inflammatory response to *C. albicans*, it is
176 dispensable for governing phagocyte killing of this organism.

177 **EGFR activity is required for the epithelial cell response to IL-17A.** Many of the
178 chemokines that were suppressed by gefitinib treatment are known to be induced by IL-17A, a
179 cytokine that plays a central role in the host defense against OPC (22-24). We therefore
180 investigated whether EGFR is required for oral epithelial cells to respond to IL-17A. When oral
181 epithelial cells were stimulated with IL-17A and TNF α in the absence of *C. albicans*, EGFR was
182 autophosphorylated for 60 min, after which phosphorylation returned to basal levels (Fig. 6A,

183 Fig. S6). Stimulation of uninfected epithelial cells with IL-17A and TNF α also induced the
184 production of CXCL8/IL-8, CCL20, and GM-CSF (Fig. 6B). This stimulation was almost completely
185 blocked when the epithelial cells were treated with gefitinib (Fig. 6C). Thus, activation of EGFR is
186 required for IL-17A to induce a proinflammatory response in oral epithelial cells.

187

188 **Discussion**

189 Oral epithelial cells play a central role in orchestrating the host defense against *C. albicans*
190 during OPC (2, 4, 25). Here, we found that EphA2 and EGFR form a complex in oral epithelial
191 cells. When these cells are infected with *C. albicans*, EphA2 and EGFR functionally interact to
192 induce a pro-inflammatory response. Previously, we found that EphA2 is required for *C. albicans* to
193 stimulate EGFR (15). Here, we determined that EGFR is in turn necessary for *C. albicans* to
194 induce prolonged activation of EphA2. This finding suggests that the initiation of an antifungal
195 proinflammatory response in the oral cavity requires two signals, one induced by EphA2 binding
196 to fungal β -glucans and the other induced by EGFR interacting with fungal invasins.

197 EphA2 and EGFR are known to interact in epithelial cell cancers, especially those that
198 have become resistant to EGFR inhibitors (26, 27). In these cells, siRNA knockdown of EphA2
199 restores sensitivity to EGFR inhibition. Interestingly, treatment of these malignant cell lines with
200 soluble EFNA1 has the same effect as EphA2 siRNA, presumably because EFNA1 induces
201 EphA2 endocytosis and subsequent degradation. Our data indicate that *C. albicans* activates
202 EphA2 differently than EFNA1 because binding of *C. albicans* stabilizes EphA2 and prevents its
203 degradation. The sustained EphA2 protein levels likely contribute to the prolonged EphA2
204 signaling induced by *C. albicans* infection.

205 Functioning as a receptor for fungal β glucans, EphA2 initiates the epithelial cell production
206 of chemokines and pro-inflammatory cytokines in response to *C. albicans* overgrowth (15). The
207 finding that EphA2 and EGFR interact prompted us to investigate whether EGFR also mediates
208 the production of pro-inflammatory mediators. Indeed, we found that knockdown of EGFR with

209 siRNA or inhibition of EGFR with gefitinib significantly reduced *C. albicans*-induced production of
210 CXCL8/IL-8 and CCL20 *in vitro*. Infection with the *als3Δ/Δ* mutant also induced less chemokine
211 secretion by oral epithelial cells, suggesting that activation of EGFR is necessary for secretion of
212 CXCL8/IL-8 and CCL20. However, gefitinib treatment had no effect on epithelial cell release of
213 IL-1 α and IL-1 β , whereas infection with the *als3Δ/Δ* mutant decreased the release of these
214 cytokines, an effect that was similar to siRNA knockdown of EphA2 (15). A potential explanation
215 for this result is that treatment with gefitinib caused a 20% \pm 8% increase in epithelial cell damage
216 due to the wild-type strain (n=9, $p < 0.0001$ by the Student's t-test), whereas infection with the
217 *als3Δ/Δ* null mutant caused significantly less damage to oral epithelial cells relative to the wild-
218 type strain (6). Similarly, siRNA knockdown of EphA2 reduced the extent of *C. albicans* induced
219 epithelial cell damage(15). Thus, we speculate that while the secretion of CXCL8/IL-8 and CCL20
220 in response to *C. albicans* is induced by activation of EGFR, the release of IL-1 α and IL-1 β is
221 stimulated by epithelial cell damage.

222 The central role of EGFR in the host inflammatory response was also demonstrated in the
223 mouse model of OPC, where treatment with gefitinib inhibited phosphorylation of both EphA2 and
224 EGFR, and reduced the tissue levels of CXCL1/KC, IL-1 α , IL-1 β , IL-17A, and IL-23p19. As a
225 result, the accumulation of neutrophils and inflammatory monocytes in the oral tissues was
226 dramatically decreased. It was notable that treatment with gefitinib only inhibited a subset of the
227 inflammatory mediators induced by *C. albicans* infection; the tissue levels of CCL2, CCL3, CCL4
228 and S100A8 in the gefitinib treated mice were not significantly different from control mice. This
229 results suggests that EGFR activation is require for the production of a subset of inflammatory
230 mediators *in vivo* and that other inflammatory mediators are induced by an EGFR-independent
231 pathway. EGFR has previously been found to be important for the production of CXCL8/IL-8 and
232 CXCL10 by pulmonary epithelial cells infected with influenza and rhinovirus. In contrast to
233 *C. albicans*, which appears to activate EGFR directly (5), these viruses activate EGFR indirectly

234 by stimulating a metalloproteinase that cleaves an EGFR proligand that in turn binds to EGFR
235 (28, 29).

236 We observed that stimulation of uninfected epithelial cells with IL-17A and TNF α induced
237 the phosphorylation of EGFR. Moreover, gefitinib blocked the release of CXCL8/IL-8, CCL20,
238 and GM-CSF by uninfected cells that had been stimulated with IL-17A and TNF α . These data
239 indicate that EGFR phosphorylation is required for at least some of the epithelial cell responses
240 to IL-17A stimulation. Lee et al. (30) found similarly that in a colonic epithelial cell line, the
241 combination of IL-17A and TNF α induces EGFR phosphorylation and that treatment with an
242 EGFR kinase inhibitor decrease IL-17A-induced release of CXCL8/IL-8 and CXCL10. These
243 authors suggested that EGFR potentiates and prolongs ERK signaling induced by IL-17A, leading
244 to chemokine secretion.

245 Our current results combined with our previous data (15) suggest a more nuanced model
246 for how oral epithelial cells respond to *C. albicans* overgrowth during OPC (Fig 7). In this model,
247 *C. albicans* β -glucans initially activate EphA2. Subsequently, when *C. albicans* forms hyphae, it
248 expresses invasins such as Als3 that activate EGFR and sustain EphA2 activation, leading to
249 activation of the MEK1/2, c-Fos, and STAT3 signaling pathways, ultimately resulting in the release
250 of proinflammatory mediators by the infected epithelial cells. EGFR is also activated by the IL-17A
251 that is produced by intraepithelial lymphocytes, leading to further amplification of the epithelial cell
252 proinflammatory response. The overall result is the secretion of chemokines, proinflammatory
253 cytokines, and host defense peptides as well as recruitment of phagocytes to the focus of
254 infection, leading to inhibition and eventual killing of the fungus.

255 While receptor-mediated induction of the proinflammatory response is likely beneficial to
256 the host, activation of EphA2 and EGFR may also be beneficial to the fungus. The interaction of
257 EphA2 and EGFR with *C. albicans* activates the clathrin-dependent endocytosis pathway in the
258 epithelial cells, leading to rearrangement of the actin cytoskeleton and formation of pseudopods
259 that engulf *C. albicans* and pull it into the epithelial cell (31). This process contributes to the

260 pathogenicity of the fungus because the internalized organism is hidden from phagocytes and
261 can utilize the epithelial cell as a source of nutrients (32).

262 This model explains the modest effect of gefitinib on oral fungal burden during OPC.
263 Although EGFR inhibition impaired the host inflammatory response to *C. albicans*, this negative
264 effect was counteracted by reduced fungal invasion of the epithelium. Based on this model,
265 therapeutic strategies to block the interaction of fungi with host receptors should be evaluated for
266 their effects on both the host inflammatory response and fungal invasion.

267

268 **Materials and Methods**

269 **Ethics statement.** All animal work was approved by the Institutional Animal Care and
270 Use Committee (IACUC) of the Los Angeles Biomedical Research Institute. The collection of
271 blood from human volunteers for neutrophil isolation was also approved by the Institutional
272 Review Board of the Los Angeles Biomedical Research Institute.

273 **Fungal strains and epithelial cells.** The *C. albicans* wild type strain SC5314 (33), the
274 *als3Δ/Δ* mutant, and the *als3Δ/Δ+pALS3* complemented strain (6) were used. For the
275 experiments, the *C. albicans* cells were grown for 18 h in yeast extract-peptone dextrose (YPD)
276 in a shaking incubator at 30°C. The fungal cells were harvested by centrifugation, washed twice
277 with phosphate-buffered saline (PBS), and counted using a hemacytometer.

278 The OKF6/TERT-2 immortalized human oral epithelial cell line was kindly provided by J.
279 Rheinwald (Harvard University, Cambridge, MA) (34) and was cultured as previously described
280 (20). OKF6/TERT-2 cells were authenticated by RNA-Seq (35) and tested for mycoplasma
281 contamination.

282 **Inhibitor and agonists.** The EGFR kinase inhibitor gefitinib (Selleckchem) was dissolved
283 in DMSO and used at a final concentration of 1 µm. It was added to the host cells 60 min prior to
284 infection or stimulation and remained in the medium for the entire incubation period. Control cells
285 were incubated with a similar concentration of DMSO at a final concentration of 0.1 %. EFNA1-Fc

286 (Acro Biosystems) was used at a final concentration of 1 μ g/ml. IL-17A and TNF α (PeproTech)
287 were used at final concentrations of 50 ng/ml and 0.5 ng/ml, respectively.

288 **siRNA.** To knockdown EGFR and IL-17RA, OKF6/TERT-2 cells were transfected with
289 siRNA as described previously (20). Briefly, the cells were grown in 6-well tissue culture plates
290 and transfected with 80 pmol EGFR siRNA (sc-29301), or a similar amount of random control
291 siRNA (sc-37007; both from Santa Cruz Biotechnology) using Lipofectamine 2000 (Thermo Fisher
292 Scientific) following the manufacturer's instructions. The extent of EGFR knockdown was verified
293 72 h later by immunoblotting with specific antibodies against EGFR. Knockdown of EGFR was >
294 80% (Fig. S1)

295 **Immunoblotting.** OKF6/TERT-2 cells in 24-well tissue culture plates were switched to
296 KSF medium without supplements for 1 h and then infected with 1×10^6 *C. albicans* yeast or
297 incubated with IL-17A and TNF α for various times as described previously (15). Next, the cells
298 were rinsed with cold HBSS containing protease and phosphatase inhibitors and detached from
299 the plate with a cell scraper. After the cells were collected by centrifugation, they were boiled in
300 sample buffer. The lysates were separated by SDS-PAGE, and phosphorylation was detected
301 by immunoblotting with specific antibodies against pEphA2 (#6347, Cell Signaling) and pEGFR
302 (#2234, Cell Signaling). Next, the blot was stripped, and the total amount of each protein was
303 detected by immunoblotting with antibodies against EphA2 (D4A2, Cell Signaling) and EGFR
304 (#4267, Cell Signaling). Each experiment was performed at least 3 times.

305 **Co-immunoprecipitation.** OKF6/TERT-2 cells were grown in 75 cm² flasks to confluence
306 and then switched to KSF medium without supplements for 3 h and then infected with 1×10^8
307 *C. albicans* yeast. After 30 or 90 min. OKF6/TERT-2 were washed with ice-cold cold PBS (with
308 Mg²⁺, and Ca²⁺), scraped, and lysed with 100 μ l ice-cold 5.8% octyl β -D-glucopyranoside (0479-
309 5g; VWR) in the present of protease/phosphatase inhibitors. Whole cells lysates were precleared
310 with 20 μ l of protein A/G plus (sc-2003; Santa Cruz Biotechnology) at 4°C for 30 minutes. Bead-
311 protein mix was centrifuged at 3000 rpm for 30 sec at 4°C and supernatants were collected. 2 μ g

312 of anti-EGFR antibody (sc-101; Santa Cruz Biotechnology), or anti-EphA2 antibody (#6347, Cell
313 Signaling) respectively, was added to 500 µg of proteins, and incubated on a rotator at 4°C for 2
314 hours. 25µl of protein A/G plus was added to each immunoprecipitation sample and incubated for
315 an additional hour at 4°C. Samples were pelleted at 3000 rpm for 30 sec, and washed 3 times in
316 500 µl of ice-cold 1.5% octyl β-D-glucopyranoside. Proteins were eluted with 30 µl of 2X SDS
317 buffer, and heated at 90°C for 5 minutes. Samples were centrifuged at 3000 rpm for 30 sec, and
318 supernatants were collected, and separated by SDS-PAGE, and analyzed as described above.

319 **Measurement of epithelial cell endocytosis.** The endocytosis of *C. albicans* by oral
320 epithelial cells was quantified as described previously (36). OKF6/TERT-2 oral epithelial cells
321 were grown to confluence on fibronectin-coated circular glass coverslips in 24-well tissue culture
322 plates and then infected for 120 min with 2×10^5 yeast-phase *C. albicans* cells per well, after
323 which they were fixed, stained, and mounted inverted on microscope slides. The coverslips were
324 viewed with an epifluorescence microscope, and the number of endocytosed organisms per high-
325 power field was determined, counting at least 100 organisms per coverslip. Each experiment was
326 performed at least 3 times in triplicate.

327 **Cytokine and chemokine measurements *in vitro*.** Cytokine levels in culture
328 supernatants were determined as previously described (15). Briefly OKF6/TERT-2 cells in a 96-
329 well plate infected with *C. albicans* at a multiplicity of infection of 5. After 8 h of infection, the
330 medium above the cells was collected, clarified by centrifugation and stored in aliquots at -80 °C.
331 The concentration of inflammatory cytokines and chemokines in the medium was determined
332 using the Luminex multiplex assay (R&D Systems).

333 **Epithelial cell damage.** The effects of gefitinib on extent of epithelial cell damage caused
334 by *C. albicans* was determined by our previously described ^{51}Cr release assay (20). OKF6/TERT-
335 2 cells in a 24-well plate were loaded with ^{51}Cr overnight. The next day, they were incubated with
336 gefitinib or diluent and then infected with *C. albicans* at a multiplicity of infection of 10. After 8 h
337 of infection, the medium above the epithelial cells was collected and the epithelial cells were lysed

338 with RadiacWash (Biodex). The amount of ^{51}Cr released into the medium and remaining in the
339 cells was determined with a gamma counter, and the percentage of ^{51}Cr released in the infected
340 cells was compared to the release by uninfected epithelial cells. The experiment was performed
341 3 times in triplicate.

342 **Mouse model of oropharyngeal candidiasis.** 6 week old male *BALB/c* mice were
343 purchased from Taconics. OPC was induced in mice as described previously (20, 21). Starting
344 on day -2 relative to infection, the mice were randomly assigned to receive gefitinib or no
345 treatment. Gefitinib was administered by adding the drug to the powdered chow diet at final
346 concentration of 200 parts-per-million. For inoculation, the animals were sedated, and a swab
347 saturated with 2×10^7 *C. albicans* cells was placed sublingually for 75 min. Mice were sacrificed
348 after 1 day of infection. The tongues were harvested, weighed, homogenized and quantitatively
349 cultured. The researchers were not blinded to the experimental groups because the endpoints
350 (oral fungal burden, cytokine levels, and leukocyte numbers) were an objective measure of
351 disease severity.

352 **Cytokine and chemokine measurements *in vivo*.** To determine the whole tongue
353 cytokine and chemokine protein concentrations, the mice were orally infected with *C. albicans* as
354 above. After 1 day of infection, the mice were sacrificed, and their tongues were harvested,
355 weighed and homogenized. The homogenates were cleared by centrifugation and the
356 concentration of inflammatory mediators was measured using a multiplex bead array assay (R&D
357 Systems) as previously described (15, 37).

358 **Flow cytometry of infiltrating leukocytes.** The number of phagocytes in the mouse
359 tongues were characterized as described elsewhere (38). Briefly, mice were orally infected with
360 *C. albicans* as described above. After 1 d of infection, the animals were administered a sublethal
361 anesthetic mix intraperitoneally. The thorax was opened, and a part of the rib cage removed to
362 gain access to the heart. The vena cava was transected and the blood was flushed from the
363 vasculature by slowly injecting 10 mL PBS into the right ventricle. The tongue was harvested and

364 cut into small pieces in 100 μ L of ice-cold PBS. 1 mL digestion mix (4.8 mg/ml Collagenase IV;
365 Worthington Biochem, and 200 μ g/ml DNase I; Roche Diagnostics, in 1x PBS) was added after
366 which the tissue was incubated at 37°C for 45 min. The resulting tissue suspension was then
367 passed through a 100 μ m cell strainer. The single-cell suspensions were incubated with rat anti-
368 mouse CD16/32 (2.4G2; BD Biosciences) for 10 min in FACS buffer at 4°C to block Fc receptors.
369 For staining of surface antigens, cells were incubated with fluorochrome-conjugated (FITC, PE,
370 PE-Cy7, allophycocyanin [APC], APC-eFluor 780,) antibodies against mouse CD45 (30-F11; BD
371 Biosciences), Ly6C (AL-21; BD Biosciences), Ly6G (1A8, BioLegend), CD11b (M1/70;
372 eBioscience), and CD90.2 (30-H12; BioLegend). After washing with FACS buffer, the cell
373 suspension was stained with a LIVE/DEAD fluorescent dye (7-AAD; BD Biosciences) for 10 min.
374 The stained cells were analyzed on a 2-laser LSRII flow cytometer (BD Biosciences), and the
375 data were analyzed using FACS Diva (BD Biosciences) and FlowJo software (Treestar). Only
376 single cells were analyzed, and cell numbers were quantified using PE-conjugated fluorescent
377 counting beads (Spherotech).

378 **Phagocyte killing assay.** The effects of gefitinib on neutrophil killing of *C. albicans* were
379 determined by our previously described method (20). Briefly, neutrophils were isolated from the
380 blood of healthy volunteers and incubated with gefitinib or diluent in RPMI 1640 medium plus 10%
381 fetal bovine serum for 1 h at 37°C. Next, the neutrophils were mixed with an equal number of
382 serum-opsonized *C. albicans* cells. After a 3 h incubation, the neutrophils were lysed by
383 sonication, and the number of viable *C. albicans* cells was determined by quantitative culture.

384 To obtain bone marrow-derived macrophages, bone marrow cells from *BALB/c* mice
385 (Taconics) were flushed from femurs and tibias using sterile RPMI 1640 medium supplemented
386 with 10% fetal bovine serum (FBS) and 2 mM EDTA onto a 50 ml screw top Falcon tube fitted
387 with a 100 μ m filter (39). 6×10^6 bone marrow cells per 75 cm² were seeded in RPMI 1640
388 supplemented with 20% FBS, 100 μ g/ml streptomycin, 100 U/ml penicillin, 2 mM Glutamine, and
389 25 ng/ml rHu M-CSF (PeproTech). After 7 days, the bone marrow derived macrophages

390 (BMDMs) were treated with gefitinib or the diluent and then incubated with serum-opsonized
391 *C. albicans* cells (multiplicity of infection 1:20) for 3 h. Next, the BMDMs were scraped, lysed by
392 sonication, and the number of viable *C. albicans* cells was determined by quantitative culture.

393 **Indirect Immunofluorescence.** To detect phosphorylation of EphA2, and EGFR in the
394 tongue of *C. albicans* infected mice, 2-μm-thick sections of OCT-embedded organs were cut with
395 a microtome and then fixed with cold acetone. Next, the cryosections were rehydrated in PBS
396 and then blocked. They were stained with primary antibodies against phosphorylated EphA2
397 (#6347, Cell Signaling) and phosphorylated EGFR (#2234, Cell Signaling) primary antibodies and
398 then rinsed and stained with an Alexa Fluor 488 secondary antibody. To detect *C. albicans*, the
399 sections were also stained with an anti-Candida antiserum (Biodesign International) conjugated
400 with Alexa Fluor 568 (Thermo Fisher Scientific). The sections were imaged by confocal
401 microscopy. To enable comparison of fluorescence intensities among slides, the same image
402 acquisition settings were used for each experiment. To determine corrected total cell
403 fluorescence the integrated density was subtracted by the selected cell area which was multiplied
404 by mean fluorescence of background readings using ImageJ (40).

405 **Statistics.** At least three biological replicates were performed for all *in vitro* experiments
406 unless otherwise indicated. Data were compared by Mann-Whitney corrected for multiple
407 comparisons using GraphPad Prism (v. 6) software. P values < 0.05 were considered statistically
408 significant.

409 **Data Availability.** The raw data that support the findings of this study are available from
410 the corresponding authors upon request.

411

412 **Acknowledgments**

413 This work was supported in part by NIH grant K99DE026856 to M.S, and R01DE022600
414 and R01AI124566 to S.G.F. M.D.L. was supported by the LA BioMed Summer Fellowship
415 Program. We thank S.W. French and E. Vitocruz for histopathology, and members of the Division

416 of Infectious Diseases at Harbor-UCLA Medical Center for critical suggestions. The content is
417 solely the responsibility of the authors and does not necessarily represent the official views of the
418 National Institutes of Health.

419

420 **Competing interests**

421 S.G.F. is a co-founder of and shareholder in NovaDigm Therapeutics, Inc., a company that is
422 developing a vaccine against mucosal and invasive *Candida* infections.

423

424 **References**

425 1. Peters BA, Wu J, Hayes RB, Ahn J. 2017. The oral fungal mycobiome: characteristics
426 and relation to periodontitis in a pilot study. *BMC Microbiology* 17:157.

427 2. Verma A, Gaffen SL, Swidergall M. 2017. Innate immunity to mucosal *Candida*
428 infections. *J Fungi* 3.

429 3. Bongomin F, Gago S, Oladele RO, Denning DW. 2017. Global and Multi-National
430 Prevalence of Fungal Diseases—Estimate Precision. *Journal of Fungi* 3:57.

431 4. Swidergall M, Filler SG. 2017. Oropharyngeal Candidiasis: Fungal Invasion and
432 Epithelial Cell Responses. *PLoS Pathogens* 13:e1006056.

433 5. Zhu W, Phan QT, Boontheung P, Solis NV, Loo JA, Filler SG. 2012. EGFR and HER2
434 receptor kinase signaling mediate epithelial cell invasion by *Candida albicans* during
435 oropharyngeal infection. *Proc Natl Acad Sci U S A* 109:14194-9.

436 6. Phan QT, Myers CL, Fu Y, Sheppard DC, Yeaman MR, Welch WH, Ibrahim AS,
437 Edwards JE, Jr., Filler SG. 2007. Als3 is a *Candida albicans* invasin that binds to
438 cadherins and induces endocytosis by host cells. *PLoS Biol* 5.

439 7. Sun JN, Solis NV, Phan QT, Bajwa JS, Kashleva H, Thompson A, Liu Y, Dongari-
440 Bagtzoglou A, Edgerton M, Filler SG. 2010. Host Cell Invasion and Virulence Mediated
441 by *Candida albicans* Ssa1. *PLoS Pathogens* 6:e1001181.

442 8. Lionakis MS, Iliev ID, Hohl TM. 2017. Immunity against fungi. *JCI Insight* 2:93156.

443 9. Lionakis MS, Levitz SM. 2017. Host Control of Fungal Infections: Lessons from Basic
444 Studies and Human Cohorts. *Annu Rev Immunol* 13:042617-053318.

445 10. Swidergall M, Ernst JF. 2014. Interplay between *Candida albicans* and the antimicrobial
446 peptide armory. *Eukaryot cell* 13:950-957.

447 11. Gladiator A, Wangler N, Trautwein-Weidner K, LeibundGut-Landmann S. 2013. Cutting
448 edge: IL-17-secreting innate lymphoid cells are essential for host defense against fungal
449 infection. *J Immunol* 190:521-5.

450 12. Verma AH, Richardson JP, Zhou C, Coleman BM, Moyes DL, Ho J, Huppler AR, Ramani
451 K, McGeachy MJ, Mufazalov IA, Waisman A, Kane LP, Biswas PS, Hube B, Naglik JR,
452 Gaffen SL. 2017. Oral epithelial cells orchestrate innate type 17 responses to *Candida*
453 albicans through the virulence factor candidalysin. *Sci Immunol* 2.

454 13. Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, Lindemann MJ, Ho AW, Hai JH, Yu JJ,
455 Jung JW, Filler SG, Masso-Welch P, Edgerton M, Gaffen SL. 2009. Th17 cells and IL-17
456 receptor signaling are essential for mucosal host defense against oral candidiasis. *J Exp
457 Med* 206:299-311.

458 14. Conti HR, Peterson AC, Brane L, Huppler AR, Hernandez-Santos N, Whibley N, Garg
459 AV, Simpson-Abelson MR, Gibson GA, Mamo AJ, Osborne LC, Bishu S, Ghilardi N,
460 Siebenlist U, Watkins SC, Artis D, McGeachy MJ, Gaffen SL. 2014. Oral-resident natural
461 Th17 cells and gammadelta T cells control opportunistic *Candida albicans* infections. *J
462 Exp Med* 211:2075-84.

463 15. Swidergall M, Solis NV, Lionakis MS, Filler SG. 2018. EphA2 is an epithelial cell pattern
464 recognition receptor for fungal beta-glucans. *Nat Microbiol* 3:53-61.

465 16. Sabet O, Stockert R, Xouri G, Brüggemann Y, Stanoev A, Bastiaens PI. 2015.
466 Ubiquitination switches EphA2 vesicular traffic from a continuous safeguard to a finite
467 signalling mode. *Nat Commun* 6.

468 17. Stallaert W, Brüggemann Y, Sabet O, Baak L, Gattiglio M, Bastiaens PIH. 2018. Contact
469 inhibitory Eph signaling suppresses EGF-promoted cell migration by decoupling EGFR
470 activity from vesicular recycling. *Science Signaling* 11.

471 18. Larsen AB, Pedersen MW, Stockhausen MT, Grandal MV, van Deurs B, Poulsen HS.
472 2007. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-
473 induced cancer cell motility. *Mol Cancer Res* 5:283-93.

474 19. Watkins TN, Gebremariam T, Swidergall M, Shetty AC, Graf KT, Alqarihi A, Alkhazraji S,
475 Alsaadi AI, Edwards VL, Filler SG, Ibrahim AS, Bruno VM. 2018. Inhibition of EGFR
476 Signaling Protects from Mucormycosis. *MBio* 9.

477 20. Solis NV, Swidergall M, Bruno VM, Gaffen SL, Filler SG. 2017. The Aryl Hydrocarbon
478 Receptor Governs Epithelial Cell Invasion during Oropharyngeal Candidiasis. *MBio*
479 8:00025-17.

480 21. Solis NV, Filler SG. 2012. Mouse model of oropharyngeal candidiasis. *Nat Protoc* 7:637-
481 42.

482 22. Amatya N, Garg AV, Gaffen SL. 2017. IL-17 Signaling: The Yin and the Yang. *Trends*
483 *Immunol* 38:310-322.

484 23. Conti HR, Gaffen SL. 2015. IL-17-Mediated Immunity to the Opportunistic Fungal
485 Pathogen *Candida albicans*. *J Immunol* 195:780-8.

486 24. Sparber F, LeibundGut-Landmann S. 2015. Interleukin 17-Mediated Host Defense
487 against *Candida albicans*. *Pathogens* 4:606-19.

488 25. Naglik JR, Moyes D. 2011. Epithelial Cell Innate Response to *Candida albicans*.
489 *Advances in Dental Research* 23:50-55.

490 26. Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P,
491 Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J. 2016. EPHA2 Blockade
492 Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. *Cancer*
493 Res 76:305-18.

494 27. Koch H, Buste ME, Kramer K, Medard G, Kuster B. 2015. Chemical Proteomics
495 Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR
496 Kinase Inhibition. *J Proteome Res* 14:2617-25.

497 28. Liu K, Gualano RC, Hibbs ML, Anderson GP, Bozinovski S. 2008. Epidermal growth
498 factor receptor signaling to Erk1/2 and STATs control the intensity of the epithelial
499 inflammatory responses to rhinovirus infection. *J Biol Chem* 283:9977-85.

500 29. Kalinowski A, Ueki I, Min-Oo G, Ballon-Landa E, Knoff D, Galen B, Lanier LL, Nadel JA,
501 Koff JL. 2014. EGFR activation suppresses respiratory virus-induced IRF1-dependent
502 CXCL10 production. *Am J Physiol Lung Cell Mol Physiol* 307:L186-96.

503 30. Lee JW, Wang P, Kattah MG, Youssef S, Steinman L, DeFea K, Straus DS. 2008.
504 Differential regulation of chemokines by IL-17 in colonic epithelial cells. *J Immunol*
505 181:6536-45.

506 31. Moreno-Ruiz E, Galan-Diez M, Zhu W, Fernandez-Ruiz E, d'Enfert C, Filler SG, Cossart
507 P, Veiga E. 2009. *Candida albicans* internalization by host cells is mediated by a
508 clathrin-dependent mechanism. *Cell Microbiol* 11:1179-1189.

509 32. Mayer FL, Wilson D, Hube B. 2013. *Candida albicans* pathogenicity mechanisms.
510 *Virulence* 4:119-128.

511 33. Fonzi WA, Irwin MY. 1993. Isogenic strain construction and gene mapping in *Candida*
512 *albicans*. *Genetics* 134:717-28.

513 34. Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA, Louis DN, Li FP,
514 Rheinwald JG. 2000. Human keratinocytes that express hTERT and also bypass a
515 p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal
516 growth and differentiation characteristics. *Mol Cell Biol* 20:1436-47.


517 35. Conti HR, Bruno VM, Childs EE, Daugherty S, Hunter JP, Mengesha BG, Saevig DL,
518 Hendricks MR, Coleman BM, Brane L, Solis N, Cruz JA, Verma AH, Garg AV, Hise AG,
519 Richardson JP, Naglik JR, Filler SG, Kolls JK, Sinha S, Gaffen SL. 2016. IL-17 Receptor
520 Signaling in Oral Epithelial Cells Is Critical for Protection against Oropharyngeal
521 Candidiasis. *Cell Host Microbe* 20:606-617.

522 36. Solis NV, Park YN, Swidergall M, Daniels KJ, Filler SG, Soll DR. 2018. *Candida albicans*
523 White-Opaque Switching Influences Virulence but Not Mating during Oropharyngeal
524 Candidiasis. *Infect Immun* 86.


525 37. Break TJ, Jaeger M, Solis NV, Filler SG, Rodriguez CA, Lim JK, Lee CC, Sobel JD,
526 Netea MG, Lionakis MS. 2015. CX3CR1 is dispensable for control of mucosal *Candida*
527 *albicans* infections in mice and humans. *Infect Immun* 83:958-65.
528 38. Sparber F, LeibundGut-Landmann S. 2017. Assessment of Immune Responses to
529 Fungal Infections: Identification and Characterization of Immune Cells in the Infected
530 Tissue. *Methods Mol Biol*:167-182.
531 39. Swamydas M, Luo Y, Dorf ME, Lionakis MS. 2015. ISOLATION OF MOUSE
532 NEUTROPHILS. *Current protocols in immunology / edited by John E Coligan [et al]*
533 110:3.20.1-3.20.15.
534 40. Rueden CT, Schindelin J, Hiner MC, DeZonia BE, Walter AE, Arena ET, Eliceiri KW.
535 2017. ImageJ2: ImageJ for the next generation of scientific image data. *BMC*
536 *Bioinformatics* 18:529.

537


538




539 **Fig 1** Interactions between EGFR and EphA2. (A and B) Immunoblot analysis of EphA2
540 phosphorylation and total protein levels in oral epithelial cells after stimulation for 15 min (A) and
541 60 min (B) with ephrin A1-Fc (EFNA1-Fc) or yeast-phase *C. albicans* SC5314 (Ca). (C and D)
542 Effects of EGFR siRNA (C) and the EGFR kinase inhibitor gefitinib (GEF) (D) on the time course
543 of EphA2 and EGFR phosphorylation in oral epithelial cells infected with *C. albicans*.
544 Phosphorylation was analyzed at 30 and 90 min post-infection (p.i.). (E) Lysates of oral epithelial
545 cells infected with *C. albicans* for 30 and 90 min were immunoprecipitated (IP) with antibodies
546 against EphA2 (left) and EGFR (right), after which EphA2, and EGFR were detected by
547 immunoblotting (Top). Immunoblots of lysate prior to immunoprecipitation, demonstrating equal
548 amounts of input protein (Bottom). (F) Densitometric analysis of 3 independent immunoblots such
549 as the ones shown in (E). Results are mean \pm SD. Statistical significance relative to uninfected
550 control cells was analyzed by the Student's t test assuming unequal variances. NS; not significant.




551 **Fig 2** EphA2 and EGFR are required for induction of a pro-inflammatory response to *C. albicans*
552 by oral epithelial cells. (A) Effects of siRNA knockdown of EGFR and EphA2 on the production
553 of cytokines and chemokines by oral epithelial cell in response to 8 h of *C. albicans* infection. Box
554 whisker plots show median, interquartile range, and range of 3 experiments, each performed in
555 duplicate. (B) Inhibition of EGFR with gefitinib reduces oral epithelial cell pro-inflammatory
556 response to *C. albicans*. Shown are results of 3 experiments, each performed in duplicate. (Ca,
557 *C. albicans*; ctrl, control; GEF, Gefitinib; UNINF, uninfected). Statistical significance is indicated
558 by * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$ (Mann-Whitney test with Bonferroni
559 correction for multiple comparisons).




560 **Fig 3** Infection of oral epithelial cells with the *C. albicans* *als3Δ/Δ* null mutant induces only
561 transient phosphorylation of EphA2 and a diminished proinflammatory response. (A). Immunoblot
562 analysis showing the effects of the indicated *C. albicans* strains on the phosphorylation of EGFR
563 after 90 min of infection (WT; wild-type strains DAY185). (B) Epithelial cell endocytosis of the
564 indicated *C. albicans* strains after 120 min of infection. Data are the combined results of three
565 experiments, each performed in triplicate. (C) Immunoblot analysis showing the time course of
566 EphA2 phosphorylation in oral epithelial cells that had been infected with wild-type and *als3Δ/Δ*
567 mutant strains of *C. albicans* for the indicated times. (D) Oral epithelial cell production of
568 chemokines and cytokines after 8 h of infection with the indicated *C. albicans* strains. Data are
569 the results of 3 experiments, each performed in duplicate. Statistical significance is indicated by
570 **** $P < 0.0001$ (Mann-Whitney test with Bonferroni correction for multiple comparisons).




571 **Fig 4** Pharmacological inhibition of EGFR reduces EphA2 phosphorylation and oral fungal burden
572 during OPC. (A) Confocal images of thin sections of the tongues of immunocompetent mice that
573 were administered gefitinib and then infected with *C. albicans* for 1 d. The thin sections were
574 stained for pEGFR, or pEphA2 (green) and *C. albicans* (red). Scale bar, 100 μ m. (B)
575 Quantification of corrected total cell fluorescence of pEGFR and pEphA2 in the oral mucosa of
576 mice with OPC. Results are the combined analysis of a total of 6 mice per condition from 2
577 separate experiments. (C) Oral fungal burden of control and gefitinib-treated mice after 1 d of
578 infection. Results are median \pm interquartile range of at total of 14 mice per group from two
579 independent experiments. The y-axis is set at the limit of detection (100 CFU/g tissue). Statistical
580 significance is indicated by * $P < 0.05$, ** $P < 0.01$ (Mann-Whitney test).



581 **Fig 5** Pharmacological inhibition of EGFR inhibits innate antifungal responses during OPC. (A-C)
582 Levels of chemokines and cytokines (A), neutrophils (B), and inflammatory monocytes (C) in the
583 tongues of control and gefitinib-treated mice treated with OPC after 1 d of infection. Scatter plots
584 show median and interquartile range of a total of seven mice in each group from two independent
585 experiments. Statistical significance is indicated by *P < 0.05, **P < 0.01 (Mann-Whitney test with
586 Bonferroni correction for multiple comparisons).



587 **Fig 6** Interaction between EGFR and IL-17 in the epithelial cell response to *C. albicans*. (A)
588 Immunoblot showing the time course of EGFR phosphorylation in oral epithelial cells that were
589 exposed to IL-17A and TNF α for the indicated times. (B) Effects of stimulating oral epithelial cells
590 with IL-17A alone or in combination with TNF α for 8 h on secretion of CXCL8/IL-8, CCL20, and
591 GM-CSF. (C) Inhibitory effects of gefitinib on oral epithelial cells secretion of the indicated
592 inflammatory mediators after 8 h of stimulation with IL-17A and TNF α . Results in (B and C) are
593 the combined data from 3 independent experiments, each performed in triplicate. Statistical
594 significance is indicated by * $P < 0.05$, ** $P < 0.001$, *** $P < 0.0001$ (Mann-Whitney test with
595 Bonferroni correction for multiple comparisons).



596 **Fig 7** Model of the interactions of *C. albicans* with EphA2 and EGFR during OPC. When
597 *C. albicans* interacts with EphA2 and EGFR on oral epithelial cells, there is prolonged
598 phosphorylation of EphA2, which activates the STAT3 and mitogen-activated protein kinase
599 (MAPK) pathways, leading to the production of chemokines, proinflammatory cytokines, and host
600 defense peptides. The chemokines recruit proinflammatory monocytes and neutrophils to the
601 focus of infection. Activation of EphA2 and EGFR also causes the epithelial cells to endocytose
602 *C. albicans*, which subsequently causes epithelial cell damage and leads to the release of IL-1 α
603 and IL-1 β . In response to *C. albicans* infection, leukocytes such as $\gamma\delta$ T cells, innate TCR $\alpha\beta^+$
604 cells, and type-3 innate lymphoid cells secrete IL-17A, which requires EGFR activation to amplify
605 the epithelial inflammatory response.

606 Supplemental Material

607 **Fig S1** Densitometric analysis of EphA2 phosphorylation and protein levels. (A and B).
608 Phosphorylation of EphA2 in unstimulated oral epithelial cells (UNINF) and epithelial cells
609 exposed to ephrin A1-Fc (EFNA1-Fc) or yeast-phase *C. albicans* SC5314 (Ca) for 15 min (A) and
610 60 min (B). Graphs show the relative ratio of phosphorylated EphA2 to total EphA2. (C) Effects
611 exposure to ephrin A1-Fc or yeast-phase *C. albicans* SC5314 for 60 min on total EphA2 protein
612 levels. (D) Effects of EGFR siRNA on EphA2 phosphorylation induced by *C. albicans* infection
613 for the indicated times. (E) Time course of EGFR phosphorylation induced by *C. albicans*. (F)
614 Extent of siRNA knockdown of EGFR. (G) Effects of gefitinib (GEF) on *C. albicans*-induced
615 phosphorylation of EphA2. Data are the mean \pm SD of 3 independent immunoblots. Images of
616 representative immunoblots are show in Fig. 1A-D. Statistical significance is indicated by
617 $^{**}P < 0.01$, $^{***}P < 0.001$, $^{****}P < 0.0001$ (two-tailed Student's t-test assuming unequal variances).

618

619 **Fig S2** Effects of EGFR siRNA and gefitinib on the endocytosis of *C. albicans* by oral epithelial
620 cells after 120 min. Box whisker plots show median, interquartile range, and range of 3
621 independent experiments, each performed in triplicate. Statistical significance is indicated by $^{**}P$
622 < 0.01 , $^{***}P < 0.001$ (Mann-Whitney test).

623

624 **Fig S3** The *C. albicans* *als3Δ/Δ* null mutant induces weak EGFR phosphorylation and transient
625 phosphorylation of EphA2. (A) Densitometric analysis of EGFR phosphorylation in oral epithelial
626 cells that had been infected with the indicated strains of *C. albicans* for 90 min. (B) Time course
627 of EphA2 phosphorylation in oral epithelial cells that had been infected with the wild-type and
628 *als3Δ/Δ* mutant strain for the indicated times. Data are the mean \pm SD of 3 independent
629 immunoblots. Images of representative immunoblots are show in Fig. 3A and C. Statistical
630 significance is indicated by $^{*}P < 0.05$, $^{**}P < 0.01$ (two-tailed Student's t-test assuming unequal
631 variances).

632 **Fig S4** Gating strategies used to identify Ly6C^{hi} inflammatory monocytes and Ly6C⁺ neutrophils
633 in the flow cytometric analysis of the tongue digests.

634

635 **Fig S5** Gefitinib has no effect on the killing of *C. albicans* by human neutrophils (A) or mouse
636 bone marrow derived macrophages (BMDM) (B). Data are the combined results of 3 experiments,
637 each performed in duplicate. Statistical significance was analyzed by the two-tailed Student's
638 t-test assuming unequal variances. NS, not significant.

639

640 **Fig. S6** IL-17A and TNF α stimulate the phosphorylation of EGFR. Densitometric analysis of
641 EGFR phosphorylation in uninfected oral epithelial cells that had been incubated with IL-17A and
642 TNF α for the indicated times (min). Data are the mean \pm SD of 3 independent immunoblots. An
643 images of a representative immunoblot is show in Fig. 6A. Statistical significance is indicated by
644 *P < 0.05, **P < 0.01 (two-tailed Student's t-test assuming unequal variances).

645